酪氨酸激酶抑制剂分子库列表,美国Selleck高特异性分子库/高通量筛选列表,赛导通生物科技现货供应

 

首页 >> 分子库/高通量筛选 >> 酪氨酸激酶抑制剂分子库

 

 

酪氨酸激酶抑制剂分子库 (96孔板)产品目录号. L1800

粉末:

剂量 价格

1mg/well ¥ 41580

2mg/well ¥ 67473

预溶在DMSO中:

剂量 价格

100μL/well (10mM solution) ¥ 27783

250μL/well (10mM solution) ¥ 42903

Customize Your Library

Contact Us

描述&优势

86种酪氨酸激酶抑制剂的独特集合,可用于高通量筛选和高内涵筛选 。

通过前期临床研究和临床实验,生物活性和安全性得到验证。

其中一些抑制剂已经得到FDA批准。

作用于酪氨酸激酶,如EGFR,VEGFR,SRC,c-Met,和JAK 。

结构多样,药效显著,可渗透细胞。

具有充分详细的结构说明,IC50值,及客户反馈资料。

NMR和HPLC技术保证产品高纯度。

产品详细信息

配制: 86种酪氨酸激酶抑制剂制成冻干粉或预溶在DMSO溶液中。

96-孔板: 是

储存: -80°C 长期储存

稳定性: 6个月

发货: 蓝冰物流

包装: 惰性气体

酪氨酸激酶抑制剂分子库目录册

下载酪氨酸激酶抑制剂分子库目录册 - SDF格式下载酪氨酸激酶抑制剂分子库目录册 - XLSX格式

酪氨酸激酶抑制剂分子库全部组成

 

 

下载产品目录册及宣传资料

 

使用我公司Selleck产品的论文

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

[Ramin Nazarian,Hubing Shi et al. nature. 2010 December;468:973-979]

Targeting Mitotic Exit Leads to Tumor Regression In Vivo: Modulation by Cdk1, Mastl,and the PP2A/B55α,β Phosphatase

[Eusebio Manchado,María Guillamot et al. Cancer Cell. 2010 December;18:641-654]

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

[V Serra, M Scaltriti et al. Oncogene. 2011;1]

Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability

[Daniel Corta´zar,Christophe Kunz et al. Nature. 2011 February;470:419-423]

Identification and Characterization of Persistent Intracellular Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitor Activity

[Yasuhiro Koh, Hillel Haim et al. Antimicrobial agents and chemotherapy. 2011 Jan;55:42-49]

Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro

[Nadine Ce´cile Luise Zembruski,Gabriele Bu¨chel et al. Journal Antimicrob Chemother. 2011 January;11]

The Anandamide Effect on NO/cGMP Pathway in Human Platelets

[Maria Grazia Signorello,Enrica Giacobbe et al. Journal of Cellular Biochemistry. 2011;112:924-932]

Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer

[Ali Naderi, Kee Ming Chia et al. Breast Cancer Research. 2011;13:762-770]

Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF

 

Write a comment

Comments: 0



赛导通生物科技联系方式:


上海市黄浦区江西中路261号509室,

近南京东路外滩


电话 400-168-1698


传真 021 3326 0586


邮箱: info@selleck.cn 

 技术: tech@selleck.cn



Selleck癌症肿瘤研究周刊


Stu.la 司途拉生物
Stu.la 司途拉生物